1. Home
  2. PANW vs AZN Comparison

PANW vs AZN Comparison

Compare PANW & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Palo Alto Networks Inc.

PANW

Palo Alto Networks Inc.

HOLD

Current Price

$289.94

Market Cap

234.5B

Sector

Technology

ML Signal

HOLD

Logo AstraZeneca PLC

AZN

AstraZeneca PLC

HOLD

Current Price

$180.45

Market Cap

316.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PANW
AZN
Founded
2005
1992
Country
United States
United Kingdom
Employees
N/A
96100
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
234.5B
316.4B
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
PANW
AZN
Price
$289.94
$180.45
Analyst Decision
Buy
Strong Buy
Analyst Count
39
1
Target Price
$216.28
N/A
AVG Volume (30 Days)
8.0M
1.9M
Earning Date
05-19-2026
04-29-2026
Dividend Yield
N/A
1.73%
EPS Growth
N/A
N/A
EPS
0.79
N/A
Revenue
$2,273,100,000.00
N/A
Revenue This Year
$24.93
$10.34
Revenue Next Year
$19.97
$6.43
P/E Ratio
$368.28
$31.91
Revenue Growth
29.04
N/A
52 Week Low
$139.57
$68.62
52 Week High
$302.95
$212.71

Technical Indicators

Market Signals
Indicator
PANW
AZN
Relative Strength Index (RSI) 67.09 48.19
Support Level $179.81 $174.60
Resistance Level $302.95 $191.50
Average True Range (ATR) 11.72 3.02
MACD -1.67 -0.03
Stochastic Oscillator 86.21 54.11

Price Performance

Historical Comparison
PANW
AZN

About PANW Palo Alto Networks Inc.

Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three-fourths of the Global 2000.

About AZN AstraZeneca PLC

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Share on Social Networks: